Aetna Medical Policy Updates – April 2021

Click here to view the Aetna Medical Policy Updates »

April 2020 Aetna Medical Policy Updates:

• Abatacept (Orencia)
• Abatacept (Orencia) [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Alpha 1-Antitrypsin Inhibitor Therapy
• Anakinra (Kineret)
• Antepartum Fetal Surveillance
• Attention Deficit/Hyperactivity Disorder
• Bevacizumab (Avastin) for Non-Ocular Indications
• Botulinum Toxin
• Botulinum Toxin [Medicare] – Medical Clinical Policy Bulletins | Aetna
• BRCA Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy
• Breast Reconstructive Surgery
• Cardiac Catheter Ablation Procedures
• Cataract Removal Surgery
• Cemiplimab (Libtayo) – Medical Clinical Policy Bulletins | Aetna
• Certolizumab Pegol (Cimzia)
• Chronic Vertigo
• Cognitive Rehabilitation
• Color-Flow Doppler Echocardiography in Adults
• Cosmetic Surgery
• Deep Brain Stimulation
• Diabetes Tests, Programs and Supplies
• Dorsal Column Stimulation
• Drug Testing in Pain Management and Substance Use Disorder Treatment – Medical Clinical Policy Bulletins | Aetna
• Electrical Stimulation for Xerostomia
• Enbrel (Etanercept)
• Eribulin Mesylate (Halaven)
• Erythropoiesis Stimulating Agents
• Erythropoiesis Stimulating Agents [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Evoked Potential Studies
• External Breast Prosthesis
• Fetal Fibronectin, Inflammatory Biomarkers, and Salivary Estriol Testing for Preterm Labor
• Gastroesophageal Reflux Disease (GERD): Treatment Devices
• Gender Reassignment Surgery
• Genetic Testing
• Golimumab (Simponi and Simponi Aria)
• Gonadotropin-Releasing Hormone Analogs and Antagonists
• Helicobacter Pylori Infection Testing
• Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
• Hematopoietic Colony-Stimulating Factors (CSFs)
• Hematopoietic Colony-Stimulating Factors (CSFs) [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Hepatitis A Vaccine
• Hereditary Angioedema
• Hereditary Transthyretin-Mediated (hATTR) Amyloidosis – Medical Clinical Policy Bulletins | Aetna
• High Intensity Focused Ultrasound
• High-Frequency Pulsed Electromagnetic Stimulation
• Hippotherapy
• Human Papillomavirus (HPV) Vaccine
• Hyperbaric Oxygen Therapy (HBOT)
• Infliximab – Medical Clinical Policy Bulletins | Aetna
• Infliximab [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Influenza Vaccine
• Infusion Pumps
• Inpatient Admission Prior to Surgery (Preop Days)
• Ixabepilone (Ixempra)
• Lutetium Lu 177 Dotatate (Lutathera) – Medical Clinical Policy Bulletins | Aetna
• Lysosomal Storage Disorders Treatments
• Multiple Sclerosis
• Multiple Sclerosis [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Natalizumab (Tysabri)
• Natalizumab (Tysabri) [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Negative Pressure Wound Therapy
• Oxaliplatin (Eloxatin)
• Oxygen
• Paclitaxel, Albumin-Bound (Abraxane)
• Paclitaxel, Albumin-Bound (Abraxane) [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Parenteral Immunoglobulins
• Parenteral Immunoglobulins [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Pembrolizumab (Keytruda)
• Percutaneous Mitral Valve Repair
• Phonophoresis
• Phototherapy and Photochemotherapy (PUVA) for Skin Conditions
• Physical Therapy
• Plerixafor (Mozobil) Injection
• Pool Therapy, Aquatic Therapy or Hydrotherapy
• Positron Emission Tomography (PET)
• Progestins
• Prothrombin Time (INR) Home Testing Devices
• Psoriasis and Psoriatic Arthritis: Targeted Immune Modulators
• Psoriasis and Psoriatic Arthritis: Targeted Immune Modulators [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Quantitative EEG (Brain Mapping)
• Ramucirumab (Cyramza)
• Reflex Sympathetic Dystrophy Diagnosis
• Reslizumab (Cinqair)
• Rilonacept (Arcalyst)
• Rituximab (Rituxan)
• Rituximab [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Romidepsin (Istodax)
• Secukinumab (Cosentyx)
• Serum and Urine Marker Screening for Down Syndrome
• Somatostatin Analogs
• Synagis (Palivizumab)
• Temozolomide (Temodar)
• Tocilizumab (Actemra)
• Tocilizumab (Actemra) [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Tofacitinib (Xeljanz)
• Trastuzumab (Herceptin), Ado-Trastuzumab (Kadcyla) and Pertuzumab (Perjeta)
• Trastuzumab (Herceptin), Trastuzumab-anns (Kanjinti), Ado-Trastuzumab (Kadcyla), Pertuzumab (Perjeta) and Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Tumor Scintigraphy
• Vagus Nerve Stimulation
• Vascular Endothelial Growth Factor Inhibitors for Ocular Indications
• Vascular Endothelial Growth Factor Inhibitors for Ocular Indications [Medicare] – Medical Clinical Policy Bulletins | Aetna
• Visudyne (Verteporfin) Photodynamic Therapy

Click here to view the Aetna Medical Policy Updates »

Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.

Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!

Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.

Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.